Skip to Content

Trumenba Approval History

FDA Approved: Yes (First approved October 29, 2014)
Brand name: Trumenba
Generic name: meningococcal group B vaccine
Company: Pfizer Inc.
Treatment for: Meningococcal Meningitis Prophylaxis

Trumenba (meningococcal group B vaccine) is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in adolescents and young adults.

Development History and FDA Approval Process for Trumenba

DateArticle
Apr 23, 2018 Pfizer Granted FDA Breakthrough Therapy Designation for Trumenba (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years
Oct 29, 2014Approval FDA Approves Trumenba - First Vaccine to Prevent Serogroup B Meningococcal Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide